Squarepoint
MRSN

Squarepoint’s Mersana Therapeutics MRSN Stock Holding History

Squarepoint’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-484
Closed -$17.3K – 5118
2024
Q4 		$17.3K Sell
484
-2,781
-85% -$144K ﹤0.01% 4944
2024
Q3 		$154K Sell
3,265
-6,847
-68% -$302K ﹤0.01% 3775
2024
Q2 		$508K Buy
+10,112
New +$731K ﹤0.01% 3069
2024
Q1 		– Sell
-547
Closed -$31.7K – 4386
2023
Q4 		$31.7K Buy
+547
New +$22K ﹤0.01% 3888
2023
Q3 		– Sell
-16,729
Closed -$1.38M – 4074
2023
Q2 		$1.38M Buy
16,729
+16,240
+3,321% +$2.38M ﹤0.01% 1929
2023
Q1 		$50.3K Sell
489
-3,413
-87% -$479K ﹤0.01% 3057
2022
Q4 		$572K Buy
3,902
+3,287
+534% +$556K ﹤0.01% 2194
2022
Q3 		$104K Sell
615
-8,440
-93% -$1.37M ﹤0.01% 2788
2022
Q2 		$1.05M Sell
9,055
-10,505
-54% -$988K 0.01% 1575
2022
Q1 		$1.95M Buy
19,560
+16,893
+633% +$1.97M 0.01% 1174
2021
Q4 		$415K Buy
+2,667
New +$519K ﹤0.01% 2268
2021
Q3 		– Sell
-1,700
Closed -$577K – 3231
2021
Q2 		$577K Sell
1,700
-517
-23% -$196K ﹤0.01% 2023
2021
Q1 		$897K Buy
2,217
+410
+23% +$199K 0.01% 1597
2020
Q4 		$1.2M Buy
1,807
+1,019
+129% +$567K 0.01% 1202
2020
Q3 		$367K Sell
788
-250
-24% -$126K ﹤0.01% 1650
2020
Q2 		$607K Buy
1,038
+554
+114% +$189K 0.01% 1199
2020
Q1 		$71K Buy
+484
New +$84.6K ﹤0.01% 1691

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Squarepoint's MRSN Position: Q1 2025 in Review

Squarepoint sold out of Mersana Therapeutics (MRSN) in Q1 2025, closing a stake of 484 shares — an estimated $17.3K sold.

Squarepoint first reported a position in MRSN in Q1 2020 and held it in 17 quarters. The position peaked at $1.95M in Q1 2022. 108 funds tracked by Wall St. Rank hold MRSN as of Q1 2025.

  • Squarepoint reported no remaining Mersana Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Squarepoint sold 484 Mersana Therapeutics shares in Q1 2025, an estimated $17.3K.
  • Squarepoint first reported a position in Mersana Therapeutics in Q1 2020 and held it in 17 quarters.
  • Squarepoint's Mersana Therapeutics position peaked at $1.95M in Q1 2022.
  • 108 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2025.

Based on Squarepoint's 13F filing for Q1 2025, filed 15 May 2025.